Teva Pharmaceutical Industries LimitedTEVA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · Israel · tevapharm.com
Teva Pharmaceutical Industries is transforming into an innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years it has innovated in neuroscience and immunology while providing complex generic medicines, biosimilars and pharmacy brands worldwide. The NYSE line is an ADR; the shares are also listed on the Tel Aviv Stock Exchange.
Key ratios
Operating cash flow growth
36.6%TTM
2025
32.2%2024
-8.9%2023
-14.0%
FCF / Sales
6.7%2025
2024
4.5%2023
5.3%
Net margin
8.2%2025
2024
-9.9%2023
-3.5%
ROA
6.2%2025
2024
5.1%2023
4.6%
ROE
20.8%2025
2024
-28.3%2023
-7.4%
Revenue growth
4.1%TTM
2025
4.3%2024
4.4%2023
6.2%
Recent news
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Teva Announces Successful Pricing of $4.9 Billion (Equivalent) Senior Notes
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for its Anti-IL-15 Antibody, Further Validating its Pipeline-in-a-Product Potential
Track TEVA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer